重视介入与靶向和免疫联合治疗在中晚期肝细胞癌中的应用前景

Attach importance to application prospect of combining interventional therapy with targeted therapy and immunotherapy on intermediate-advanced hepatocellular carcinoma

介入治疗是中晚期肝细胞癌患者治疗最主要的手段,包括肝动脉化疗栓塞术(transarterial chemoembolization,TACE)、肝动脉灌注化疗(hepatic artery infusion chemotherapy,HAIC)、局部消融治疗和选择性内放射治疗(selective internal radiation therapy,SIRT)等,能有效改善患者的临床症状和延长生存期。以靶向治疗和免疫治疗为代表的肝细胞癌系统性治疗近年来取得明显进展,尤其是靶向和免疫联合治疗呈现出显著疗效,而局部介入治疗联合靶向和免疫治疗正成为新的研究热点。本文就这一方面作一个专题评述。

Interventional therapy is the most important treatment for patients with intermediate-advanced hepatocellular carcinoma,in-cluding transarterial chemoembolization(TACE),hepatic artery infusion chemotherapy(HAIC),local ablation and selective internal radia-tion therapy(SIRT),which can effectively relieve the clinical symptoms and prolong the survival time of patients.The systemic treatment of hepatocellular carcinoma represented by targeted therapy and immunotherapy has made significant progress in recent years.Especially,the combination of targeted therapy and immunotherapy has shown significant efficacy,and local interventional therapy combined with targeted therapy and immunotherapy is becoming the focus of research.This article makes a special review on this aspect.